Valion Bio, Inc. Adjustments to Additional Paid in Capital, Warrant Issued
Valion Bio, Inc. (VBIO) reported Adjustments to Additional Paid in Capital, Warrant Issued of $375.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-14
- Valion Bio, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2026-03-31 was $375.00K, a 244.04% increase year-over-year.
- Valion Bio, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-09-30 was $93.00K.
- Valion Bio, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-06-30 was $36.00K, a 48.57% decline year-over-year.
- Valion Bio, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-03-31 was $109.00K.
- Valion Bio, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2025 was $9.40M, a 13334.29% increase from fiscal 2024.
- Valion Bio, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $70.00K, a 80.72% decline from fiscal 2023.
- Valion Bio, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $363.00K.
- Valion Bio, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2021 was $608.00K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2026-03-31 | $375.00K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $9.40M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $93.00K 10-Q · filed 2025-11-14 | $129.00K derived: sum of 2 quarters · filed 2026-08-14 | $238.00K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $36.00K 10-Q · filed 2026-08-14 | $145.00K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $109.00K 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | $70.00K 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $70.00K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $70.00K 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $363.00K 10-K · filed 2025-03-21 | |||
| 2023-09-30 | $168.00K 10-Q · filed 2024-11-14 | |||
| 2023-03-31 | $195.00K 10-Q · filed 2024-11-14 | |||
| 2021-12-31 | $608.00K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $52.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |